title: A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
abstract: BACKGROUND
  The vascular disrupting agent combretastatin A4 phosphate (CA4P) causes major regression of animal tumours when given as combination therapy.
  
  
  METHODS
  Patients with advanced cancer refractory to standard therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclitaxel, or paclitaxel, followed by carboplatin.
  
  
  RESULTS
  Combretastatin A4 phosphate was escalated from 36 to 54 mg m(-2) with the carboplatin area under the concentration curve (AUC) 4-5, from 27 to 54 mg m(-2) with paclitaxel 135-175 mg m(-2), and from 54 to 72 mg m(-2) with carboplatin AUC 5 and paclitaxel 175 mg m(-2). Grade 3 or 4 neutropenia was seen in 17%, and thrombocytopenia only in 4% of 46 patients. Grade 1-3 hypertension (26% of patients) and grade 1-3 tumour pain (65% of patients) were the most typical non-haematological toxicities. Dose-limiting toxicity of grade 3 hypertension or grade 3 ataxia was seen in two patients at 72 mg m(-2). Responses were seen in 10 of 46 (22%) patients with ovarian, oesophageal, small-cell lung cancer, and melanoma.
  
  
  CONCLUSIONS
  The combination of CA4P with carboplatin and paclitaxel was well tolerated in the majority of patients with adequate premedication and had antitumour activity in patients who were heavily pretreated.
authors.affiliation: Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK. grustin@nhs.net
authors.forename: G J
authors.initials: GJ
authors.lastname: Rustin
authors.forename: G
authors.initials: G
authors.lastname: Shreeves
authors.forename: P D
authors.initials: PD
authors.lastname: Nathan
authors.forename: A
authors.initials: A
authors.lastname: Gaya
authors.forename: T S
authors.initials: TS
authors.lastname: Ganesan
authors.forename: D
authors.initials: D
authors.lastname: Wang
authors.forename: J
authors.initials: J
authors.lastname: Boxall
authors.forename: L
authors.initials: L
authors.lastname: Poupard
authors.forename: D J
authors.initials: DJ
authors.lastname: Chaplin
authors.forename: M R L
authors.initials: MR
authors.lastname: Stratford
authors.forename: J
authors.initials: J
authors.lastname: Balkissoon
authors.forename: M
authors.initials: M
authors.lastname: Zweifel
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D001259:Ataxia / Q000139:chemically induced; D016190:Carboplatin / Q000627:therapeutic use* / Q000633:toxicity; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008017:Life Expectancy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology; D017239:Paclitaxel / Q000627:therapeutic use* / Q000633:toxicity; D018579:Patient Selection; D013267:Stilbenes / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D013267:Stilbenes; D016190:Carboplatin; C058728:fosbretabulin; D017239:Paclitaxel
references.citation: Anticancer Drugs. 1993 Feb;4(1):19-25
references.pmid: 8457709
references.citation: Anticancer Res. 2000 Jan-Feb;20(1A):229-33
references.pmid: 10769660
references.citation: Cancer Res. 1999 Apr 1;59(7):1626-34
references.pmid: 10197639
references.citation: Radiother Oncol. 2001 Aug;60(2):155-61
references.pmid: 11439210
references.citation: Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1557-64
references.pmid: 16884365
references.citation: Clin Cancer Res. 2005 Feb 15;11(4):1527-33
references.pmid: 15746056
references.citation: Eur J Cancer. 2000 Sep;36(14):1833-43
references.pmid: 10974632
references.citation: J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91
references.pmid: 15547181
references.citation: Science. 2006 Sep 22;313(5794):1785-7
references.pmid: 16990548
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2823-30
references.pmid: 12807935
references.citation: J Clin Endocrinol Metab. 2007 Aug;92(8):2902-9
references.pmid: 17550961
references.citation: Clin Oncol (R Coll Radiol). 2007 Aug;19(6):443-56
references.pmid: 17459681
references.citation: J Clin Oncol. 2003 Dec 1;21(23):4428-38
references.pmid: 14645433
references.citation: Vascul Pharmacol. 2009 Nov-Dec;51(5-6):337-43
references.pmid: 19737629
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2831-42
references.pmid: 12807936
references.citation: Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):211-7
references.pmid: 17448875
references.citation: Cancer Res. 2002 Jun 15;62(12):3408-16
references.pmid: 12067983
references.citation: Eur J Cancer. 2004 Jan;40(2):284-90
references.pmid: 14728944
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2815-22
references.pmid: 12807934
references.citation: J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s
references.pmid: 12743133
references.citation: Br J Cancer. 2003 Apr 22;88(8):1160-7
references.pmid: 12698178
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Int J Cancer. 2002 May 1;99(1):1-6
references.pmid: 11948484